Comparing the current results to its competitors, Veracyte Inc reported Revenue increase in the 2 quarter 2026 by 23.45 % year on year. The sales growth was above Veracyte Inc 's competitors' average revenue growth of 11.46 %, achieved in the same quarter.
Veracyte Inc 's Comment on Competition and Industry Peers
The company competes with various organizations utilizing next-generation sequencing technology and other methods to measure genomic biomarkers. Its Afirma test competes with Interpace Diagnostics Group, Inc. and ThyroSeq, marketed by Sonic Healthcare Limited. The Decipher Prostate test competes with genomic testing offerings from Myriad Genetics, Inc. and MDxHealth, SA for localized prostate cancer. Traditional pathology methods and AI-powered image analysis companies such as ArteraAI also represent competitive alternatives. In bladder cancer, no direct competitor provides genomic testing for the intended use population; however, DNA mutational analysis and traditional clinical methods are employed. The primary competitor in minimal residual disease (MRD) testing for muscle-invasive bladder cancer (MIBC) is Natera, Inc. Potential future competitors include Natera, Inc., Guardant Health, Inc., Exact Sciences Corporation, Personalis, Myriad Genetics, Neogenomics, Inc., Quest Diagnostics, and Billion-. Competitors identified in company filings include ArteraAI, Exact Sciences Corporation, Guardant Health, Inc., Interpace Diagnostics Group, Inc., MDxHealth, SA, Myriad Genetics, Inc., Natera, Inc., Neogenomics, Inc., Personalis, Quest Diagnostics, Sonic Healthcare Limited, and ThyroSeq.
Thermo Fisher Scientific Inc operates as a global leader in scientific research and services by delivering an extensive range of high-quality scientific instruments, reagents, consumables, and software solutions tailored to industries such as healthcare, pharmaceuticals, biotechnology, academia, and government. The company enhances its value proposition through a comprehensive suite of services, including laboratory outsourcing, scientific consulting, and data analysis, which help streamline research and development processes for its customers. By leveraging advanced technology and deep industry expertise, Thermo Fisher empowers researchers and organizations to drive innovation and accelerate scientific discovery.
Natera Inc operates as a genetic testing company that provides non-invasive screening and diagnostic tests for reproductive health, oncology, and organ transplantation. The company's business model is built around offering cost-effective and accurate genetic testing solutions for both patients and healthcare providers. Natera primarily generates revenue by selling its proprietary tests and associated analysis services to customers, including hospitals, laboratories, and physicians.
Myriad Genetics Inc's business model revolves around providing molecular diagnostic testing services and developing innovative precision medicine solutions that help identify and personalize treatment options for patients across various medical specialties.
23andMe Holding Co operates as a direct-to-consumer genetic testing company. Their business model primarily revolves around selling DNA testing kits to individuals, who can then provide a saliva sample and receive reports on their genetic ancestry, health predispositions, and other genetic traits. The company generates revenue by charging customers for the testing kits, as well as offering additional subscription-based services for ongoing access to updated reports and insights.
Sources:
Veracyte Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Veracyte Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
